At Metabolon, they pioneered the practice of metabolomics, the study of chemical processes that involve metabolites. Metabolites are the small end products of metabolism. Today, they are paving the way for a new, more profound understanding of health, wellness and disease, through the identification and analysis of metabolites, the small-molecule end products of metabolism.
For nearly 20 years, they have worked to develop the world’s most diverse and rich metabolomics knowledgebase. Their proprietary library of more than 5,200 biologically relevant metabolites makes it possible for them to provide you with an exceedingly comprehensive, high-fidelity view of the metabolome, resulting in a deeper understanding of complex systems. Every day, their work accelerates research and leads to successes in biopharma, population health, consumer products, agriculture, wellness and academic and government research sectors. They offer scalable, customizable metabolomics solutions across the research continuum from discovery through clinical trials to in-market life cycle management.
Their work in metabolite discovery has been documented in more than 2,000 publications and includes high-impact journals such as Cell, Nature and Science. With their clients, Metabolon has explored 500+ conditions and unlocked actionable insights related to the behavior of diseases such as cancer, diabetes, epilepsy, autism, NASH, sickle cell disease, high blood pressure and many more.
Every day, their team of highly-specialized scientists draw actionable insights from functional metabolites. This work has enabled modern science to gain a foothold in their understanding of complex disease, ultimately leading to the creation of new treatments that impact individuals and communities globally.See more